

A discovery and IP development company, advancing the science behind medical cannabis



Stock Info

Canada CSE:VRT

U.S OTC:VRTHF

Germany FRT:2VP

Shares Outstanding 71.697M*

Market Capitalization 7.170M

Fiscal Year End April 30th

*12/20/2018

2018 News Highlights

- Veritas Confirms Readiness for Human Trials of CTL-X for Pain
- Veritas Announces Investment Into Cannabis Growing Facility Under Health Canada License
- Veritas Pharma Enters Into Share Purchase Agreement with 3 Carbon Extractions Inc.
- Veritas' Cannevert to Offer Testing Services for Cannabis & Hemp Licensed Producers; Corporate Update

Investor Relations

Contact: Sam Eskandari
Telephone: +1.416.918.6785
Email: ir@veritaspharmainc.com
Web: veritaspharmainc.com

About Veritas Pharma

- Solving the critical need for real science to support claims surrounding medical cannabis, developing the most effective proprietary and patented cultivars (strains) targeting pain, sleep, substance addiction, and senior/palliative care.
- Research and commercialization led by strong management and renowned group of scientists with a low cost research and development model to help drive shareholder value
- Established exclusive partner alliance and investment in high-level R&D arm, Cannevert Therapeutics, bringing together veteran academic pharmacologists, anesthesiologists & chemists
- Has already progressed from Chemical and Biological (animal testing) assays to clinical trials for pain
- Clinical trials to demonstrate real therapeutic utilities, with the potential to deliver the industry's first set of standards providing doctors with necessary evidence to confidently recommend Veritas' proprietary strains
- Speed-to-market employs a whole plant methodology, translating to years faster to market, estimated at one-tenth the time of traditional pharma drug approval
- Making strategic investments in cannabis production facilities to meet the future R&D needs of Cannevert Therapeutics

Multi - Billion Dollar Growth Industry

- The medical marijuana market is US\$1.47 billion in North America alone¹
- Forecast 17% annual growth, with market estimated to double in size within 5 years²
- Canada has a national medical cannabis program and is currently progressing towards legalization of marijuana for recreational use
- 39 states have legalized cannabis in some form for recreational or medicinal use in the US so far

Major Growth Drivers

- Already engaged in Clinical Trials for a target strain treating Acute Pain (CTL-X), as well as establishing partnerships for cannabis production and oil extractions
- Future innovation and advancement in science related to cannabis therapeutics will accelerate patient adoption and consumption
- Opportunity exists to create new distinguishable products that are clinically tested, supported by real data to be sold or licensed to various markets for medicinal use
- Growing negative opinion regarding the use of opioids for pain will continue to drive the need for alternative medical applications such as cannabis. The global opioids market is valued at a staggering US\$34.8bn in 2015³

Leading Management

Dr. Lui Franciosi, PhD – CEO

25+ years experience conducting pharmaceutical and medical device studies in academia and industry. Previously, Chief Operating Officer of Verona Pharma PLC, London Stock Exchange (AIM: VRP). Prior, he completed his post-doctoral research in COPD progression modelling at the Clinical Pharmacology & Discovery Medicine Unit, GlaxoSmithKline, UK. Obtained his Doctorate & Masters degrees at The University of British Columbia (UBC), Canada — and pursued business studies at the University of Warwick, UK. He is currently an adjunct professor at UBC Faculty of Medicine, Department of Anesthesiology, Pharmacology & Therapeutics.

Peter McFadden, CPA, CA, TEP, MBA, HB. Comm, BSc – Interim CFO

Mr. McFadden is an experienced accounting and finance professional. He is currently a partner at McFadden, Butter & Associates CPAs Inc. He was formerly a senior manager at KPMG specializing in mergers and acquisitions and tax in Toronto. He has taught Business and Accounting courses at the Okanagan University College. Mr. McFadden holds a bachelor of Science from McMaster University, a bachelor of Commerce with honors from University of Windsor, and became a Chartered Accountant (CA) in 1983. Additionally, he obtained his Masters in Business Administration (MBA) in international Finance and Accounting in 1981.

Lorne Rosenborough - Director

Mr. Rosenborough is an experienced executive with substantial successful track record in developing and expanding startups. Mr. Roseborough is currently the CEO of Sunvault Energy Inc. (OTCBB: SVLT) in Kelowna, B.C., which focuses on bringing cost effective energy generation and storage to the solar industry. He previously held the position as a Start-up Lead Executive for Dow Corning's \$1.2 billion Semiconductor plant in Clarksville, Tennessee.

Blair Lowther - Corporate Secretary Director

Mr. Lowther is a commercial lawyer with Miller Thomson LLP in Vancouver. Currently, he is an executive with BlocPal International Inc., a Director for Sport BC, and is a Guest Lecturer & Contributing Author for the Sauder School of Business at UBC.

Nick Standish – Director

Mr. Standish brings substantial business experience as CEO of Stamatis Ventures Ltd. Through Stamatis, Mr. Standish has co-founded: Integro Management Solutions, a cannabis related management and consulting company; and Innogrow.io, an agricultural technology joint venture between Stamatis, ENVIO Systems Inc. and Miracle Valley Medicinal Alternatives.

Veritas Clinical Cannabis Development Pipelined

- Chronic Pain (Cancer Pain)
- Opioid Harm Reduction
- Sleep Disorders
- Acute Pain (CTL-X)
- Palliative Care

Confidence in Highly Credentialed Team of Scientists



- Dr. Michael J.A. Walker, PhD
- Dr. Andrew Hegle, PhD
- Dr. Scott Alexander, MBBS
- Dr. Tim Fung, PhD
- Ms. Navjot Chahal, MSc
- Dr. Richard A. Wall, PhD



"The strategic alliance that we've formed with Cannevert and its scientists will enable Veritas to be at the forefront of developing new and unique strains of medicinal cannabis. These plants will be patent protected for a variety of unmet medical needs. These scientists have indeed the rare skills necessary to make blockbuster medicines, with a history of generating over \$1 billion worth of investor value based on previous drug discoveries."

-Dr. Franciosi, PhD - CEO